Literature DB >> 12065752

NK1 receptor fused to beta-arrestin displays a single-component, high-affinity molecular phenotype.

Lene Martini1, Hanne Hastrup, Birgitte Holst, Alberto Fraile-Ramos, Mark Marsh, Thue W Schwartz.   

Abstract

Arrestins are cytosolic proteins that, upon stimulation of seven transmembrane (7TM) receptors, terminate signaling by binding to the receptor, displacing the G protein and targeting the receptor to clathrin-coated pits. Fusion of beta-arrestin1 to the C-terminal end of the neurokinin NK1 receptor resulted in a chimeric protein that was expressed to some extent on the cell surface but also accumulated in transferrin-labeled recycling endosomes independently of agonist stimulation. As expected, the fusion protein was almost totally silenced with respect to agonist-induced signaling through the normal Gq/G11 and Gs pathways. The NK1-beta-arrestin1 fusion construct bound nonpeptide antagonists with increased affinity but surprisingly also bound two types of agonists, substance P and neurokinin A, with high, normal affinity. In the wild-type NK1 receptor, neurokinin A (NKA) competes for binding against substance P and especially against antagonists with up to 1000-fold lower apparent affinity than determined in functional assays and in homologous binding assays. When the NK1 receptor was closely fused to G proteins, this phenomenon was eliminated among agonists, but the agonists still competed with low affinity against antagonists. In contrast, in the NK1-beta-arrestin1 fusion protein, all ligands bound with similar affinity independent of the choice of radioligand and with Hill coefficients near unity. We conclude that the NK1 receptor in complex with arrestin is in a high-affinity, stable, agonist-binding form probably best suited to structural analysis and that the receptor can display binding properties that are nearly theoretically ideal when it is forced to complex with only a single intracellular protein partner.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065752     DOI: 10.1124/mol.62.1.30

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

1.  Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes.

Authors:  Sonia Terrillon; Michel Bouvier
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

Review 2.  Identifying ligand-specific signalling within biased responses: focus on δ opioid receptor ligands.

Authors:  I Charfi; N Audet; H Bagheri Tudashki; G Pineyro
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 3.  Nanobody stabilization of G protein-coupled receptor conformational states.

Authors:  Jan Steyaert; Brian K Kobilka
Journal:  Curr Opin Struct Biol       Date:  2011-07-21       Impact factor: 6.809

4.  beta-Arrestin 1 and 2 stabilize the angiotensin II type I receptor in distinct high-affinity conformations.

Authors:  S J Sanni; J T Hansen; M M Bonde; T Speerschneider; G L Christensen; S Munk; S Gammeltoft; J L Hansen
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

5.  Control of signalling efficacy by palmitoylation of the rat Y1 receptor.

Authors:  Nicholas D Holliday; Helen M Cox
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

6.  SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor.

Authors:  M E Bradley; M E Bond; J Manini; Z Brown; S J Charlton
Journal:  Br J Pharmacol       Date:  2009-04-24       Impact factor: 8.739

7.  Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors.

Authors:  Mounia Azzi; Pascale G Charest; Stéphane Angers; Guy Rousseau; Trudy Kohout; Michel Bouvier; Graciela Piñeyro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-17       Impact factor: 11.205

8.  Arrestin binds to different phosphorylated regions of the thyrotropin-releasing hormone receptor with distinct functional consequences.

Authors:  Brian W Jones; Patricia M Hinkle
Journal:  Mol Pharmacol       Date:  2008-04-15       Impact factor: 4.436

9.  Activation of an alpha2A-adrenoceptor-Galphao1 fusion protein dynamically regulates the palmitoylation status of the G protein but not of the receptor.

Authors:  Elaine Barclay; Mark O'Reilly; Graeme Milligan
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

10.  Biased Gs versus Gq proteins and β-arrestin signaling in the NK1 receptor determined by interactions in the water hydrogen bond network.

Authors:  Louise Valentin-Hansen; Thomas M Frimurer; Jacek Mokrosinski; Nicholas D Holliday; Thue W Schwartz
Journal:  J Biol Chem       Date:  2015-08-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.